A Phase I clinical trial to investigate the safety and tolerability of NK105 when co-administered with carboplatin once per week to Japanese patients with advanced solid cancers.

ippon Kayaku Co., Ltd.0 个研究点目标入组 18 人开始时间: 2016年5月18日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•A solid cancer has been confirmed by tissue and/or cytological diagnosis.
•There is no standard therapy, or even if available, the cancer was refractory to it or it was intolerable to the patient.
•ECOG Performance Status of 0-1.

•Grade >=2 sensory neuropathy.
•Use of any other therapeutic agents within 28 days prior to enrollment.
•A history of drug hypersensitivity requiring systemic treatment, such as anaphylaxis, etc., or a history of hypersensitivity to carboplatin formulations or conventional paclitaxel formulations.
•A complication of heart failure or ischemic heart disease (Class 2 or higher in the NYHA cardiac function classification), or a need for new treatment within 6 months before enrollment.
•Use of a systemic antimicrobial to treat an infection within 14 days prior to enrollment.
•Presence of pleural effusion, ascites or cardiac effusion for which drainage is considered necessary.
•Presence of CNS metastasis accompanied by symptoms.

发起方

ippon Kayaku Co., Ltd.